Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Single Dose Study of BIBR 1048 MS (Dabigatran Etexilate) in Healthy Males
NCT02170116Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Nov 1998
- Primary completion
- Dec 1998
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, double-blind trial of dabigatran in thromboembolism (6 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Prothrombin Time up to 24 hours and Activated Partial Thromboplastin Time up to 24 hours. Started Nov 1998; status: completed.
02
Drugs
dabigatran
03
Conditions
thromboembolism
Beyond the preview
Go deeper on NCT02170116.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02170116.